Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

(Reuters) - The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.